Scinai Immunotherapeutics Reports Strong First-Half 2025 Results with Revenue Growth and Enhanced Financial Position

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) reported substantial financial progress for the six months ended June 30, 2025, with revenues reaching $773,000 compared to $284,000 in the same period last year. This 172% growth reflects the continued expansion of the company's contract development and manufacturing organization (CDMO) business, which has secured $1.0 million in service orders through August 2025. The company's strategic focus on both therapeutic development and CDMO services has positioned it for sustained growth in the competitive biopharmaceutical market.

The company's research and development expenses decreased significantly to $1.24 million from $2.79 million in the prior-year period, demonstrating improved operational efficiency while maintaining progress on key programs. Marketing, general and administrative expenses increased to $1.26 million from $1.00 million, reflecting investments in business development and corporate infrastructure. The net loss narrowed to $4.13 million compared to $4.48 million a year earlier, indicating improved financial management and cost control measures.

Scinai's cash position strengthened considerably, with cash and equivalents totaling $989,000 as of June 30, 2025. The company further enhanced its liquidity by raising an additional $4.2 million in July and August under its Standby Equity Purchase Agreement. This capital infusion provides crucial resources for advancing the company's anti-IL-17 NanoAb program and supporting ongoing operations. The financial stability achieved through these measures reduces execution risk and enhances the company's ability to pursue strategic opportunities.

The company has made significant progress in its therapeutic development pipeline, filing new patents under its collaboration with Max Planck Institute. Scinai is actively pursuing up to €27 million in grant funding to support clinical trials and pipeline development, which could substantially accelerate its research programs without diluting shareholder value. The company maintains access to investor resources through its newsroom at https://ibn.fm/SCNI, providing transparency and regular updates to the investment community.

Scinai's dual business model, combining proprietary drug development with CDMO services, creates a diversified revenue stream while leveraging shared expertise and infrastructure. The CDMO unit's growth demonstrates the market demand for specialized biological drug development services, particularly for early-stage biotech companies. This business segment provides near-term revenue while the therapeutic pipeline advances through development stages, creating a balanced approach to value creation in the competitive biopharmaceutical landscape.